PE20210552A1 - Anticuerpos anti-transtiretina - Google Patents
Anticuerpos anti-transtiretinaInfo
- Publication number
- PE20210552A1 PE20210552A1 PE2020000481A PE2020000481A PE20210552A1 PE 20210552 A1 PE20210552 A1 PE 20210552A1 PE 2020000481 A PE2020000481 A PE 2020000481A PE 2020000481 A PE2020000481 A PE 2020000481A PE 20210552 A1 PE20210552 A1 PE 20210552A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- transthyretin
- refers
- monoclonal antibody
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un anticuerpo monoclonal aislado que compite por la union a transtiretina (TTR) humana con el anticuerpo monoclonal 18C5. Los ejemplos de dichos anticuerpos se unen a un epitope dentro de los residuos aminoacidos 101-109 de la region madura de la SEQ ID NO: 26. Tambien se refiere a un acido nucleico que codifica la cadena pesada y/o la cadena liviana de dicho anticuerpo, un vector de expresion recombinante, una celula hospedadora transformada con el vector, un metodo para humanizar un anticuerpo, un metodo para producir un anticuerpo humanizado, un metodo para detectar la presencia o ausencia de depositos de transtiretina y un metodo de diagnostico de amiloidosis mediada por transtiretina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762569436P | 2017-10-06 | 2017-10-06 | |
US201762598965P | 2017-12-14 | 2017-12-14 | |
PCT/US2018/054720 WO2019071205A1 (en) | 2017-10-06 | 2018-10-05 | ANTI-TRANSTHYRETIN ANTIBODY |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210552A1 true PE20210552A1 (es) | 2021-03-17 |
Family
ID=65994817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000481A PE20210552A1 (es) | 2017-10-06 | 2018-10-05 | Anticuerpos anti-transtiretina |
Country Status (15)
Country | Link |
---|---|
US (1) | US11267877B2 (es) |
EP (1) | EP3691447A4 (es) |
JP (1) | JP7357609B2 (es) |
KR (1) | KR20200074956A (es) |
CN (1) | CN111315213B (es) |
AU (1) | AU2018345806A1 (es) |
BR (1) | BR112020006434A2 (es) |
CA (1) | CA3077361A1 (es) |
CU (1) | CU20200021A7 (es) |
MX (1) | MX2020003041A (es) |
PE (1) | PE20210552A1 (es) |
SA (1) | SA520411703B1 (es) |
SG (1) | SG11202002489YA (es) |
WO (1) | WO2019071205A1 (es) |
ZA (1) | ZA202002141B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
KR20200074956A (ko) | 2017-10-06 | 2020-06-25 | 프로테나 바이오사이언시즈 리미티드 | 항-트랜스타이레틴 항체 |
PE20211453A1 (es) | 2017-11-29 | 2021-08-05 | Prothena Biosciences Ltd | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina |
IL298135A (en) | 2020-05-12 | 2023-01-01 | Neurimmune Ag | Combined treatment for ttr amyloidosis |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
WO2023205739A2 (en) * | 2022-04-20 | 2023-10-26 | Senti Biosciences, Inc. | Antigen-binding domains and methods of use thereof |
WO2024121156A1 (en) | 2022-12-05 | 2024-06-13 | Neurimmune Ag | Cyclic compounds and their use in assays for detecting antibodies |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
AU2001253158A1 (en) | 2000-04-05 | 2001-10-23 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
ATE506072T1 (de) | 2002-09-12 | 2011-05-15 | Univ California | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz |
US9535076B2 (en) | 2002-09-12 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
EP1660533A4 (en) | 2003-09-12 | 2009-10-21 | Univ California | SPECIFIC MONOCLONAL ANTIBODIES MADE FROM PROTEINS OF DIFFERENT SEQUENCES FOR HIGHLY MOLECULAR AGGREGATIVE INTERMEDIATE PRODUCTS OF AMYLOIDS |
WO2006108234A1 (en) * | 2005-04-13 | 2006-10-19 | Garvan Institute Of Medical Research | Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor |
EP2514823B1 (en) | 2006-03-03 | 2018-05-02 | ProMIS Neurosciences Inc. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
ATE495447T1 (de) * | 2006-07-03 | 2011-01-15 | Univ Johns Hopkins | Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie |
EP2548647B1 (en) | 2006-10-20 | 2018-08-15 | CLONDIAG GmbH | Assay devices and methods for the detection of analytes |
WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
AU2009301580B2 (en) | 2008-10-06 | 2015-11-26 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
JP2010195710A (ja) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
CA2753621A1 (en) | 2009-03-02 | 2010-09-10 | The University Of British Columbia | Antibodies and epitopes specific to misfolded prion protein |
TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
FI20115165A0 (fi) * | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
EP2698431B1 (en) | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP3892638A1 (en) | 2012-05-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
JP2016514091A (ja) * | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス, インコーポレイテッド | トランスサイレチン抗体およびその使用 |
JP6344773B2 (ja) * | 2013-03-12 | 2018-06-20 | 国立大学法人名古屋大学 | 植物の光合成および生産量を増加させる方法 |
WO2015010118A2 (en) | 2013-07-19 | 2015-01-22 | The University Of Texas | Transthyretin amyloid-selective and polyreactive catabodies |
EA201691060A1 (ru) * | 2013-12-20 | 2016-12-30 | Нейриммьюн Холдинг Аг | Терапия транстиретинового (ттр) амилоидоза антителами, а также антитела, полученные от человека для указанной терапии |
WO2015115331A1 (ja) * | 2014-01-29 | 2015-08-06 | 一般財団法人化学及血清療法研究所 | 抗トランスサイレチンヒト化抗体 |
WO2015115332A1 (ja) | 2014-01-29 | 2015-08-06 | 一般財団法人化学及血清療法研究所 | 抗トランスサイレチンヒト抗体 |
PL3185957T3 (pl) | 2014-08-29 | 2022-11-14 | Alnylam Pharmaceuticals, Inc. | Patisiran do zastosowania w leczeniu amyloidozy związanej z transtyretyną |
TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI711631B (zh) * | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
JP7076711B2 (ja) | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3691626A4 (en) | 2017-10-06 | 2021-06-30 | Prothena Biosciences Limited | METHODS OF DETECTION OF TRANSTHYRETINE |
KR20200074956A (ko) | 2017-10-06 | 2020-06-25 | 프로테나 바이오사이언시즈 리미티드 | 항-트랜스타이레틴 항체 |
PE20211453A1 (es) | 2017-11-29 | 2021-08-05 | Prothena Biosciences Ltd | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina |
WO2021168156A1 (en) | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Monitoring transthyretin amyloidosis |
-
2018
- 2018-10-05 KR KR1020207012722A patent/KR20200074956A/ko not_active Application Discontinuation
- 2018-10-05 PE PE2020000481A patent/PE20210552A1/es unknown
- 2018-10-05 CU CU2020000021A patent/CU20200021A7/es unknown
- 2018-10-05 US US16/753,307 patent/US11267877B2/en active Active
- 2018-10-05 BR BR112020006434-3A patent/BR112020006434A2/pt unknown
- 2018-10-05 EP EP18863984.3A patent/EP3691447A4/en active Pending
- 2018-10-05 AU AU2018345806A patent/AU2018345806A1/en active Pending
- 2018-10-05 CA CA3077361A patent/CA3077361A1/en active Pending
- 2018-10-05 JP JP2020518649A patent/JP7357609B2/ja active Active
- 2018-10-05 CN CN201880071788.1A patent/CN111315213B/zh active Active
- 2018-10-05 SG SG11202002489YA patent/SG11202002489YA/en unknown
- 2018-10-05 WO PCT/US2018/054720 patent/WO2019071205A1/en active Application Filing
- 2018-10-05 MX MX2020003041A patent/MX2020003041A/es unknown
-
2020
- 2020-04-05 SA SA520411703A patent/SA520411703B1/ar unknown
- 2020-05-04 ZA ZA2020/02141A patent/ZA202002141B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CU20200021A7 (es) | 2021-01-12 |
EP3691447A4 (en) | 2021-08-11 |
ZA202002141B (en) | 2023-01-25 |
JP7357609B2 (ja) | 2023-10-06 |
CN111315213A (zh) | 2020-06-19 |
SG11202002489YA (en) | 2020-04-29 |
CA3077361A1 (en) | 2019-04-11 |
SA520411703B1 (ar) | 2024-04-28 |
JP2020536532A (ja) | 2020-12-17 |
KR20200074956A (ko) | 2020-06-25 |
AU2018345806A1 (en) | 2020-03-12 |
EP3691447A1 (en) | 2020-08-12 |
US20200331992A1 (en) | 2020-10-22 |
CN111315213B (zh) | 2023-09-12 |
MX2020003041A (es) | 2020-10-05 |
US11267877B2 (en) | 2022-03-08 |
BR112020006434A2 (pt) | 2020-11-03 |
WO2019071205A1 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210552A1 (es) | Anticuerpos anti-transtiretina | |
AR108377A1 (es) | Proteínas de unión biespecíficas y sus usos | |
PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
MX2023001791A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
PE20181046A1 (es) | Anticuerpos anti-tigit y metodos de uso | |
AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
CU20180136A7 (es) | Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7 | |
PE20141162A1 (es) | Anticuerpos anti-il-23 | |
AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
CL2021000942A1 (es) | Anticuerpos anti-npr1 y usos relacionados. | |
NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos | |
PE20181051A1 (es) | Anticuerpo anti-epha4 | |
EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
BR112022005404A2 (pt) | Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap) | |
PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos |